| Medicare Claims | Total Spending | Drug | Drug Class | Average Cost / Patient | % Correct |
|---|---|---|---|---|---|
| 61.1M | $836M | Atorvastatin | Cardiovascular | $56 / yr | 63%
|
| 24.2M | $182M | Metformin | Endocrine | $31 / yr | 56%
|
| 28.3M | $439M | Omeprazole | Gastrointestinal | $62 / yr | 46%
|
| 44.2M | $310M | Amlodipine | Cardiovascular | $30 / yr | 40%
|
| 33.0M | $622M | Gabapentin | Neurology | $90 / yr | 40%
|
| 38.4M | $728M | Levothyroxine | Endocrine | $91 / yr | 40%
|
| 26.2M | $587M | Metoprolol | Cardiovascular | $95 / yr | 37%
|
| 36.1M | $260M | Lisinopril | Cardiovascular | $30 / yr | 35%
|
| 2.0M | $2.62B | Ozempic | Endocrine | $5,717 / yr | 32%
|
| 23.4M | $140M | Furosemide | Cardiovascular | $25 / yr | 30%
|
| 29.4M | $393M | Losartan | Cardiovascular | $55 / yr | 30%
|
| 17.1M | $12.58B | Eliquis | Cardiovascular | $4,024 / yr | 25%
|
| 4.6M | $2.83B | Lantus Solostar | Endocrine | $2,685 / yr | 18%
|
| 375K | $2.91B | Humira Pen | Antirheumatic | $56,752 / yr | 12%
|
| 6.4M | $5.23B | Xarelto | Cardiovascular | $4,154 / yr | 11%
|
| 3.8M | $3.74B | Jardiance | Cardiovascular | $4,224 / yr | 9%
|
| 3.7M | $4.70B | Trulicity | Endocrine | $7,084 / yr | 7%
|
| 4.5M | $4.06B | Januvia | Endocrine | $4,344 / yr | 4%
|
| 344K | $5.89B | Revlimid | Cancer | $129,242 / yr | 4%
|
| 231K | $3.15B | Imbruvica | Cancer | $120,958 / yr | 0%
|